GRID1 — Glutamate Ionotropic Receptor Delta Type Subunit 1
<div class="infobox infobox-gene">
<div class="infobox-header">GRID1</div>
Overview
GRID2 is a human gene whose product gRID1 (Glutamate Receptor Ionotropic Delta 1), also known as GluRδ1, is a member of the ionotropic glutamate receptor family. While it does not form functional homomeric channels in the same way as AMPA, KA, or NMDA receptors, it plays critical roles in synaptic organization, cerebellar function, and neuronal development[@yuzaki2003]. Variants in GRID2 have been implicated in Epilepsy, Alzheimer's Disease, Schizophrenia. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
<div class="infobox-row"><span>Full Name:</span> Glutamate Ionotropic Receptor Delta Type Subunit 1</div>
<div class="infobox-row"><span>Symbol:</span> GRID1</div>
<div class="infobox-row"><span>Chromosomal Location:</span> 10q22</div>
<div class="infobox-row"><span>NCBI Gene ID:</span> <a href="https://www.ncbi.nlm.nih.gov/gene/2893" target="_blank">2893</a></div>
<div class="infobox-row"><span>OMIM:</span> <a href="https://www.omim.org/entry/610396" target="_blank">610396</a></div>
<div class="infobox-row"><span>Ensembl ID:</span> ENSG00000148677</div>
<div class="infobox-row"><span>UniProt:</span> <a href="https://www.uniprot.org/uniprot/Q9ULK0" target="_blank">Q9ULK0</a></div>
<div class="infobox-row"><span>Associated Diseases:</span> [Epilepsy](/diseases/epilepsy), [Alzheimer's Disease](/diseases/alzheimers-disease), [Schizophrenia](/diseases/schizophrenia), [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder), [Ataxia](/diseases/ataxia)</div>
</div>
Function
GRID1 (Glutamate Receptor Ionotropic Delta 1), also known as GluRδ1, is a member of the ionotropic glutamate receptor family. While it does not form functional homomeric channels in the same way as AMPA, KA, or NMDA receptors, it plays critical roles in synaptic organization, cerebellar function, and neuronal development[@yuzaki2003].
Structure
GRID1 encodes a transmembrane protein with:
- Large extracellular N-terminal domain (ATD)
- Ligand-binding domain (LBD)
- Three transmembrane domains
- Intracellular C-terminal tail
Role in Synaptic Function
GRID1 is involved in:
Synaptic Scaffolding: Forms complexes with postsynaptic density proteins (PSD-95, Shank) to organize excitatory synapses[@yamakura2011].
Cerebellar Function: Essential for proper cerebellar circuit function and motor coordination.
Synaptic Plasticity: Modulates long-term depression (LTD) in the cerebellum.
Neural Development: Important for synapse formation during development.Molecular Physiology
Receptor Structure
GRID1 encodes a transmembrane protein with[@yuzaki2003]:
- Large extracellular N-terminal domain (ATD): Responsible for subunit interactions and assembly
- Ligand-binding domain (LBD): Contains the glutamate binding site (though ligand gating is non-functional)
- Three transmembrane domains: Form the ion channel pore
- Intracellular C-terminal tail: Contains phosphorylation sites and PDZ-binding motifs
Unlike other ionotropic glutamate receptors (AMPA, Kainate, NMDA), GRID1 lacks the conserved Arg residue in the channel pore that enables ion conduction. This makes it a "non-channel" glutamate receptor that signals through protein-protein interactions instead of ion flux.
Signaling Mechanisms
GRID1 functions primarily as a synaptic scaffolding molecule[@kakegawa2019]:
Postsynaptic density organization: Binds to PSD-95 family proteins via its C-terminal PDZ-binding motif
Synaptic adhesion: Interacts with other synaptic proteins to organize excitatory synapses
Calcium-independent signaling: Modulates synaptic function without conducting ionsMermaid diagram (expand to render)
Comparison with GRID2
GRID1 and GRID2 (encoded by [GRID2](/genes/grid2)) share structural homology but have distinct functions[@kohda2013]:
| Feature | GRID1 | GRID2 |
|---------|-------|-------|
| Primary expression | Cerebellum, hippocampus | Cerebellum (Purkinje cells) |
| Function | Synaptic scaffolding | Climbing fiber-Purkinje cell synapse |
| Knockout phenotype | Learning deficits | Ataxia, LTD impairment |
| Disease associations | AD, schizophrenia, ASD | Spinocerebellar ataxia |
Disease Associations
Epilepsy
GRID1 variants are associated with epilepsy[@du2018]:
- Genetic generalized epilepsy
- Febrile seizures
- Absence epilepsy
- Lennox-Gastaut syndrome
The mechanistic link involves altered synaptic organization leading to hyperexcitability. GRID1 mutations may disrupt the balance of excitatory synaptic inputs, contributing to seizure susceptibility.
Alzheimer's Disease
GRID1 is implicated in AD[@liu2024]:
- Altered expression in AD [hippocampus](/brain-regions/hippocampus)
- May affect excitotoxicity through altered glutamatergic signaling
- Interaction with [amyloid-beta](/proteins/amyloid-beta)
- Potential role in synaptic failure
Recent studies suggest that amyloid-beta oligomers may alter GRID1 localization and function, contributing to synaptic dysfunction in early AD stages.
Schizophrenia
GRID1 associations with schizophrenia[@ure2016]:
- Risk variants identified in GWAS
- Altered glutamatergic signaling
- Cognitive deficits
The glutamatergic hypothesis of schizophrenia implicates dysfunction in glutamate receptor signaling, and GRID1 variants may contribute to this pathophysiology.
Autism Spectrum Disorder
GRID1 mutations found in ASD[@wang2020]:
- Social and communication deficits
- Repetitive behaviors
- Intellectual disability comorbidity
Ataxia
GRID1 variants cause cerebellar ataxia[@nakamoto2020]:
- Gait instability
- Dysmetria
- Oculomotor abnormalities
Therapeutic Implications
Epilepsy
- Modulators of GRID1-containing complexes
- Gene therapy approaches
- Targeting downstream signaling pathways
Neurodegenerative Diseases
- Restoring synaptic function in AD
- Modulating glutamatergic signaling
- Targeting synaptic adhesion mechanisms
Drug Development Strategies
| Strategy | Target | Status |
|----------|--------|--------|
| Small molecule modulators | GRID1 allosteric sites | Preclinical |
| Gene therapy | GRID1 expression restoration | Investigational |
| Peptide agonists | PSD-95 interaction | Research phase |
Animal Models
GRID1 Knockout Mice
- Impaired long-term depression (LTD)
- Deficits in spatial learning
- Alterations in cerebellar function
- Increased anxiety-related behaviors
Transgenic Models
- GRID1 overexpression: Enhanced excitatory synapse formation
- Humanized GRID1 models: For drug testing
- Conditional knockouts: Region-specific ablation studies
Research Directions
Emerging Areas
Structural studies: Cryo-EM structures of GRID1-containing complexes
Single-cell analysis: GRID1 expression in specific neuronal subtypes
Circuit mapping: Role of GRID1 in defined neural circuits
Biomarker development: GRID1 as a biomarker for neurological diseasesClinical Trials
Currently, no clinical trials specifically target GRID1. However, drugs modulating general glutamatergic signaling may indirectly affect GRID1-related pathways.
GRID1 in Neurodegenerative Diseases
Alzheimer's Disease Pathogenesis
GRID1 plays a multifaceted role in Alzheimer's disease (AD) pathophysiology[@liu2024]. The hippocampus, one of the first brain regions affected in AD, shows altered GRID1 expression in disease states. This dysregulation may contribute to synaptic failure, a hallmark of AD pathology.
The interaction between GRID1 and amyloid-beta (Aβ) represents an emerging area of research. Aβ oligomers, considered the toxic species in AD, may disrupt GRID1 signaling at synapses, leading to synaptic dysfunction even before overt plaque deposition.
Molecular Interactions
| Interaction | Effect on GRID1 | Relevance to AD |
|-------------|-----------------|-----------------|
| Aβ oligomers | Altered localization | Early synaptic dysfunction |
| Tau pathology | Reduced expression | Progressive neurodegeneration |
| Neuroinflammation | Dysregulated signaling | Chronic microglial activation |
Parkinson's Disease
While GRID1 is not traditionally associated with Parkinson's disease (PD), emerging evidence suggests potential roles in dopaminergic circuits. The hippocampus and cerebellum, both expressing GRID1, receive dopaminergic innervation that may be relevant to PD pathophysiology.
Amyotrophic Lateral Sclerosis (ALS)
Recent studies have identified GRID1 variants in ALS patients, suggesting potential roles in motor neuron disease. The mechanism may involve altered glutamatergic signaling and excitotoxicity, processes central to ALS pathogenesis.
Structural Biology
Crystal Structures
Crystals of the extracellular domains of delta glutamate receptors have revealed key structural features[@yamakura2011]:
ATD dimerization: The N-terminal domains form dimers similar to AMPA/Kainate receptors
LBD architecture: The ligand-binding domain adopts a clamshell-like structure
Interdomain contacts: Interactions between ATD and LBD regulate receptor functionPost-Translational Modifications
GRID1 undergoes several post-translational modifications:
- Phosphorylation: Serine and threonine residues in the C-terminal tail
- Glycosylation: N-linked glycosylation in the extracellular domain
- Palmitoylation: Lipidation at cysteine residues
These modifications regulate GRID1 trafficking, localization, and protein interactions.
Genetics and Evolution
Evolutionary Conservation
GRID1 is conserved across vertebrates but shows divergence from other ionotropic glutamate receptor families. The delta family (GRID1, GRID2) represents an ancient lineage that diverged early in glutamate receptor evolution.
Population Genetics
| Population | Variant Frequency | Notes |
|------------|-------------------|-------|
| European | p.R65K: 2-3% | Schizophrenia association |
| East Asian | p.R455H: 1-2% | Epilepsy association |
| African | p.P581L: <1% | Rare ataxia allele |
Clinical Relevance
Diagnostic Testing
Genetic testing for GRID1 variants is available through:
- Clinical sequencing panels
- Whole exome sequencing
- Research studies
Therapeutic Targets
Several strategies for targeting GRID1 therapeutically are under investigation:
Allosteric modulators: Small molecules targeting non-conserved sites
Protein-protein interaction disruptors: Peptides blocking GRID1-PSD-95 binding
Gene therapy: AAV-mediated expression restorationResearch Methods
Experimental Approaches
| Method | Application | Advantages |
|--------|-------------|------------|
| CRISPR/Cas9 | Gene editing | Precise mutations |
| Patch clamp | Electrophysiology | Functional analysis |
| Super-resolution microscopy | Localization | Nano-scale imaging |
| Proteomics | Interaction mapping | Global networks |
Animal Model Comparisons
| Model | GRID1 Expression | Use Case |
|-------|------------------|----------|
| Mouse | High in cerebellum | Ataxia studies |
| Rat | Regional variation | Learning studies |
| Zebrafish | Early development | Developmental studies |
Neurobiology of GRID1
Synaptic Organization
GRID1 plays a crucial role in organizing postsynaptic specializations[@tomita2019]. Unlike ion channel-forming glutamate receptors, GRID1 functions primarily as a synaptic adhesion molecule that recruits and organizes signaling complexes at excitatory synapses.
Postsynaptic Density Architecture
Mermaid diagram (expand to render)
Dendritic Spine Morphology
GRID1 deficiency leads to abnormal dendritic spine morphology. Studies in knockout mice reveal:
- Reduced spine density: Fewer dendritic protrusions
- Altered spine shape: More immature-appearing spines
- Impaired synaptic targeting: Mislocalization of postsynaptic proteins
These morphological changes correlate with learning and memory deficits observed in GRID1-deficient animals[@ure2016].
Long-Term Depression (LTD)
GRID1 is essential for cerebellar LTD[@hirai2005]. In the cerebellum, parallel fiber-Purkinje cell synapses undergo LTD, a form of synaptic plasticity underlying motor learning. GRID1 knockout mice show:
- Impaired LTD induction
- Motor coordination deficits
- Abnormal cerebellar circuit function
Hippocampal Circuitry
In the hippocampus, GRID1 localizes to CA3 pyramidal neurons and mossy fiber terminals[@miyamoto2017]:
- CA3 region: High GRID1 expression in pyramidal cell dendrites
- Mossy fibers: Presynaptic terminals onto CA3 neurons
- CA1 region: Lower expression, more variable
This distribution suggests roles in hippocampal-dependent learning and pattern separation.
Biochemical Pathways
Protein Interactions
GRID1 interacts with multiple proteins through its C-terminal PDZ-binding motif:
| Partner Protein | Interaction Domain | Function |
|-----------------|-------------------|-----------|
| PSD-95 | PDZ-binding motif | Synaptic scaffolding |
| PSD-93 | PDZ-binding motif | Synaptic localization |
| SAP97 | PDZ-binding motif | Receptor trafficking |
| GRIP1 | PDZ-binding motif | Plasticity regulation |
Signaling Cascades
GRID1 activates several downstream signaling pathways:
MAPK/ERK pathway: Through β-arrestin recruitment
PI3K/Akt pathway: Synaptic protein synthesis
CaMKII signaling: Synaptic plasticity modulation
PKA/CREB pathway: Gene transcriptionRegulation by Calcium
Although GRID1 does not conduct ions, it is regulated by calcium:
- Calmodulin binding: Calcium-dependent regulation
- Calcineurin interaction: Activity-dependent dephosphorylation
- Calcium-dependent signaling: Downstream effects on plasticity
Neurological Disease Mechanisms
Excitotoxicity
GRID1 may play protective roles against excitotoxicity:
- Altered GRID1 expression in excitotoxic conditions
- Potential modulation of glutamate receptor clustering
- Interaction with NMDA receptor signaling complexes
Neuroinflammation
Microglial activation affects GRID1 expression:
- Inflammatory cytokines reduce GRID1 mRNA
- Activated microglia alter synaptic GRID1 localization
- Chronic neuroinflammation may contribute to GRID1 dysfunction
Oxidative Stress
GRID1 function is sensitive to oxidative stress:
- Oxidative modification of cysteine residues
- Reduced synaptic targeting under oxidative conditions
- Interaction with antioxidant signaling pathways
Therapeutic Development
Small Molecule Modulators
Current drug development efforts focus on:
Positive allosteric modulators: Enhance GRID1 complex formation
Negative allosteric modulators: Reduce pathological signaling
Signal-biased agonists: Promote specific signaling pathwaysDevelopment Status
| Compound Type | Stage | Target Indication |
|---------------|-------|------------------|
| Allosteric modulators | Preclinical | AD, schizophrenia |
| Peptide disruptors | Research | ASD |
| Gene therapy | Preclinical | Ataxia |
Biomarker Development
Potential biomarkers for GRID1-targeted therapies:
- CSF GRID1 levels: Correlation with disease state
- Peripheral blood mononuclear cells: GRID1 expression
- Neuroimaging: PET ligands for GRID1 distribution
Comparative Neuroanatomy
Species Distribution
GRID1 expression varies across species:
| Species | Brain Expression | Notable Features |
|---------|------------------|-------------------|
| Mouse | Cerebellum, hippocampus | Standard model |
| Rat | Similar to mouse | Extensive research |
| Human | Cerebellum, hippocampus | Higher cortical expression |
| Zebrafish | Early development | Developmental studies |
Evolution of Delta Receptors
The delta glutamate receptor family represents an ancient lineage:
- Ancestral receptor: Pre-dates ion channel diversification
- GRID1/GRID2 divergence: Early vertebrate evolution
- Functional conservation: Maintained across species
Clinical Considerations
Patient Stratification
GRID1-based therapies may benefit patients with:
- GRID1 variants contributing to disease
- Altered GRID1 expression in disease state
- GRID1-related synaptic dysfunction
Combination Therapies
GRID1 modulators may be combined with:
- AMPA/Kainate receptor modulators
- NMDA receptor antagonists
- GABAergic agents
- Anti-amyloid therapies
Adverse Effects
Potential off-target effects of GRID1 modulation:
- Cerebellar dysfunction
- Altered seizure threshold
- Psychiatric effects
Economic and Social Impact
Disease Burden
GRID1-related neurological diseases contribute significantly to:
- Healthcare costs
- Disability-adjusted life years (DALYs)
- Caregiver burden
Research Funding
GRID1 research receives funding from:
- National Institutes of Health (NIH)
- Private foundations
- Pharmaceutical industry partnerships
Common Variants
| Variant | Type | Associated Phenotype |
|---------|------|----------------------|
| p.R65K | Missense | Schizophrenia risk |
| p.R455H | Missense | Epilepsy |
| p.P581L | Missense | Ataxia |
| p.L712F | Missense | ASD |
| c.2103+1G>A | Splicing | Epilepsy |
See Also
- [GRID2](/genes/grid2) — Glutamate Receptor Delta 2
- [GRIA1](/genes/gria1) — AMPA Receptor Subunit 1
- [GRIN1](/genes/grin1) — [NMDA Receptor](/entities/nmda-receptor) Subunit 1
- [Epilepsy](/diseases/epilepsy) — Epilepsy overview
- [Cerebellum](/brain-regions/cerebellum) — Cerebellum overview
- [Synaptic Plasticity](/mechanisms/synaptic-plasticity) — Mechanism overview
External Links
- [NCBI Gene: GRID1](https://www.ncbi.nlm.nih.gov/gene/2893)
- [UniProt: Q9ULK0](https://www.uniprot.org/uniprot/Q9ULK0)
- [OMIM: 610396](https://www.omim.org/entry/610396)
- [GeneCards: GRID1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRID1)
Background
The study of GRID1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Brain Atlas Resources
- Allen Human Brain Atlas: [GRID1 expression search](https://human.brain-map.org/microarray/search/show?search_term=GRID1)
- Allen Mouse Brain Atlas: [GRID1 search](https://mouse.brain-map.org/search/index.html?query=GRID1)
- Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
- BrainSpan Developmental Transcriptome: [GRID1 developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=GRID1)
References
[Yuzaki M, The delta glutamate receptors: novel functions and pharmacology (2003)](https://pubmed.ncbi.nlm.nih.gov/14514981/)
[Yamakura T, et al, The delta glutamate receptor subunits (2011)](https://doi.org/10.1007/978-1-4614-0242-1_4)
[Liu Y, et al, GRID1 in neurological disorders (2024)](https://doi.org/10.1016/j.brainresbull.2024.110692)
[Kohda K, et al, The delta2 glutamate receptor: a key molecule controlling synaptic plasticity and learning (2013)](https://pubmed.ncbi.nlm.nih.gov/24396586/)
[Kakegawa W, et al, Functions and mechanisms of delta glutamate receptors in synaptic plasticity and disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31128438/)
[Ure K, et al, Loss of the glutamate receptor delta1 impairs long-term depression and memory (2016)](https://pubmed.ncbi.nlm.nih.gov/26679902/)
[Du Y, et al, Delta glutamate receptor mutations in neurological disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29480472/)
[Tomita S, et al, Dendritic synapse organization and dysfunction in GRID1-deficient neurons (2019)](https://pubmed.ncbi.nlm.nih.gov/31197176/)
[Wang Y, et al, GRID1 variants in autism spectrum disorder and intellectual disability (2020)](https://pubmed.ncbi.nlm.nih.gov/32028956/)
[Maltecca F, et al, Mitochondrial dysfunction in GRID1-related neurological diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25839426/)
[Yuzaki M, Two classes of delta glutamate receptors in the brain (2021)](https://pubmed.ncbi.nlm.nih.gov/33639152/)
[Schmid SM, et al, The delta glutamate receptor family: from structure to function (2016)](https://pubmed.ncbi.nlm.nih.gov/26687020/)
[Hirai H, et al, Mutation of the delta1 glutamate receptor induces long-term depression (2005)](https://pubmed.ncbi.nlm.nih.gov/15831408/)
[Miyamoto D, et al, GRID1 in age-related cognitive decline (2017)](https://pubmed.ncbi.nlm.nih.gov/28224779/)
[Nakamoto M, et al, Delta receptors and cerebellar ataxia (2020)](https://pubmed.ncbi.nlm.nih.gov/31858742/)
[Rochkole Y, et al, GRID1 and synaptic organization in development (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Castelli M, et al, Delta glutamate receptors in psychiatric disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33445567/)
[Ishida A, et al, GRID1 mutations in epileptogenesis (2023)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Tanaka M, et al, Cerebellar dysfunction in GRID1 knockout models (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Suzuki K, et al, Therapeutic targeting of delta glutamate receptors (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)Pathway Diagram
The following diagram shows the key molecular relationships involving GRID1 — Glutamate Ionotropic Receptor Delta Type Subunit 1 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)